DDMAC's Latest Exhibit Hall Citation Is Vectibix; Firms Try Multiple Ways To Avoid FDA At Trade Shows
This article was originally published in The Pink Sheet Daily
Executive Summary
Amgen rep's description of KRAS information as predictive of response to the colorectal cancer drug during a ASHP meeting draws a notice of violation from FDA.